Evidence map›Paper›PMID 34349859›Full record

ArticleWorld journal of oncology2021

Scalp Leiomyosarcoma: Diagnosis and Treatment During a Global Pandemic With COVID-19.

Hebah Hassan, Amit Elazar, Kazuaki Takabe, Rajiv Datta, Hideo Takahashi, Eric Seitelman

Abstract readCase Reports
In one paragraph

Article in World journal of oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Types of Cancer and Research Covered inWorld journal of oncology · 2022
    Article
  5. Article
  6. Article
  7. Infections in Hospitalized Cancer Patients.World journal of oncology · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Hebah HassanDepartment of Surgery, Mount Sinai South Nassau, Oceanside, NY, USA.
Amit ElazarDepartment of Surgery, Mount Sinai South Nassau, Oceanside, NY, USA.
Kazuaki TakabeDepartment of Surgical Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Rajiv DattaDepartment of Surgery, Mount Sinai South Nassau, Oceanside, NY, USA.
Hideo TakahashiDepartment of Surgery, Mount Sinai South Nassau, Oceanside, NY, USA.
Eric SeitelmanDepartment of Surgery, Mount Sinai South Nassau, Oceanside, NY, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Leiomyosarcoma is an aggressive, uncommon sarcoma effecting smooth muscle tissue. Prompt tissue diagnosis and staging workup are keys to preventing distant metastasis. Identification of this rare sarcoma has become increasingly difficult with decreased ability to seek out non-coronavirus disease 2019 (COVID-19) medical care. The pandemic has caused a widespread healthcare demand with providers reaching their full capacity causing care and resources to be shifted to the pandemic. We have experienced an 83-year-old male who significantly delayed to seek any medical attention for his scalp lesion for several months due to a combination of fear and decreased available appointments. Since the patient presented with a delayed scalp leiomyosarcoma, he required an extensive excision and flap reconstruction for the lesion. This case sheds light on the importance of weighing the risks and benefits associated with cancer management during the pandemic for both patients and healthcare providers. The healthcare system's response to the pandemic also played a role in this case as well, with shorter appointment times and decreased frequency of follow-up. As a result, the pandemic has had a catastrophic impact on the diagnostic pathway for cancer. This case report discusses the difficulties in diagnosing and treating a rare cancer such as scalp leiomyosarcoma amidst the global pandemic and the importance of telemedicine in improving future outcomes.

Indexed as

COVID-19PandemicScalp leiomyosarcomaTelemedicine

Identifiers

PMID34349859
PMCPMC8297053

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.